Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. (not Capricor Therapeutics, Inc.) on March 21, 2013, reporting events occurring on March 15, 2013, and March 21, 2013. The company is a biopharmaceutical entity focused on developing cenderitide, a product candidate currently seeking funding for Phase 2 clinical trials.
Key Financial Metrics and Transactions
- Debt Financing: The Company sold Secured Convertible Promissory Notes with an aggregate principal amount of $450,000 for an original issue price of $382,500 (a 15% original issue discount).
- Debt Terms: The Notes mature on March 15, 2014, bear no interest, and are secured by a blanket lien on the Company's assets.
- Liquidity: The filing does not provide current cash balances or liquidity metrics beyond the proceeds from this specific transaction.
- Compensation Adjustments: The Chief Financial Officer (CFO) reduced his monthly salary to $100 effective February 1, 2013, deferring the balance of $22,916.66 until an "Interim Financing Event" (defined as raising at least $1,000,000 in gross cash proceeds by December 31, 2013).
Material Changes and Agreements
- Convertible Note Agreement: Entered into a Convertible Note Purchase Agreement with accredited investors. The Notes automatically convert to common stock upon a Change of Control at the Closing Price, accompanied by a five-year warrant. In other Change of Control scenarios, the Company must pay 175% of the principal amount in cash.
- CEO Compensation Amendment: Modified the compensation agreement for President and CEO Darlene Horton, M.D. If a Change of Control occurs prior to December 31, 2013, she is entitled to 5% of the Company's fully-diluted common stock (in stock-for-stock transactions) or 5% of Change of Control Proceeds (in cash transactions).
- CFO Compensation Amendment: Modified the agreement for CFO Daron Evans. Similar to the CEO, he is entitled to 4.5% of fully-diluted common stock or 4.5% of Change of Control Proceeds upon a Change of Control prior to December 31, 2013. This agreement supersedes a prior Severance Benefits Agreement.
Outlook, Risks, and Contingencies
- Financing Contingency: Executive compensation deferrals and potential payouts are contingent upon the Company securing an "Interim Financing Event" of at least $1,000,000 by December 31, 2013, or completing a Change of Control.
- Operational Goal: The Company aims to secure sufficient capital to initiate and fund a Phase 2 clinical trial for cenderitide.
- Security Risk: The new debt is secured by a blanket lien on all Company assets, which may limit future borrowing capacity or asset utilization.
- Change of Control Risk: The Company faces significant cash obligations (175% of principal) or equity dilution (conversion plus warrants) if a Change of Control occurs.
Investor Verification Checklist
- Verify the total outstanding debt and any other secured liens on the Company's assets.
- Confirm the Company's current cash runway and progress toward the $1,000,000 "Interim Financing Event" target.
- Review the fully-diluted share count to assess the potential dilution impact of the CEO and CFO change-of-control provisions (5% and 4.5%, respectively).
- Monitor the status of the cenderitide Phase 2 clinical trial funding and regulatory approvals.
- Check for any subsequent filings regarding the repayment or conversion of the $450,000 in Notes.